Prognostic Value of TAPSE/sPAP Ratio, RV S′ Velocity, and RV S′/sPAP Ratio in Hospitalized Patients with COVID-19: A Retrospective Echocardiographic Analysis Hastaneye Yatırılan COVID-19 Hastalarında TAPSE/sPAP Oranı, RV S′ Hızı ve RV S′/sPAP Oranının Prognostik Değeri: Retrospektif Bir Ekokardiyografik Analiz
Genel Tip Dergisi, cilt.36, sa.2026, 2026 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 36 Sayı: 2026
- Basım Tarihi: 2026
- Doi Numarası: 10.54005/geneltip.1807952
- Dergi Adı: Genel Tip Dergisi
- Derginin Tarandığı İndeksler: Scopus, Directory of Open Access Journals, TR DİZİN (ULAKBİM), Academic Search Ultimate (EBSCO)
- Anahtar Kelimeler: COVID-19, echocardiography, prognosis, right ventricular function, RV S′/sPAP, TAPSE/ sPAP
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Aim: This study aimed to evaluate the association between the tricuspid annular plane systolic excursion (TAPSE) to systolic pulmonary artery pressure (sPAP) ratio, right ventricular (RV) S′ velocity, RV S′/sPAP ratio, and adverse clinical outcomes in hospitalized COVID-19 patients. Materials and Methods: A retrospective cohort of 100 adult patients hospitalized with laboratory-confirmed COVID-19 who underwent transthoracic echocardiography (TTE) was analyzed. Patients were classified into two groups according to clinical outcomes: adverse outcome (ICU admission, mechanical ventilation, ARDS, or in-hospital mortality) and favorable outcome. Echocardiographic parameters (TAPSE, sPAP, RV S′, TAPSE/sPAP, and RV S′/sPAP) were compared between groups, and receiver operating characteristic (ROC) curve analysis was performed to assess discriminative performance in this exploratory analysis. Results: Thirty-two patients experienced adverse outcomes. The TAPSE/sPAP ratio (0.44 ± 0.18 vs. 0.55 ± 0.22, p = 0.006), RV S′ velocity (9.17 ± 2.1 cm/s vs. 10.54 ± 2.1 cm/s, p = 0.004), and RV S′/sPAP ratio (0.28 ± 0.10 vs. 0.33 ± 0.08, p = 0.008) were significantly lower in the adverse outcome group. ROC analysis showed fair discriminative performance for TAPSE/sPAP, RV S′, and RV S′/sPAP with AUCs of 0.686, 0.691, and 0.753, respectively. Conclusion: TAPSE/sPAP, RV S′, and RV S′/sPAP are non-invasive echocardiographic markers associated with adverse outcomes in hospitalized COVID-19 patients. Their combined use may contribute to early risk stratification in an exploratory, hypothesis-generating context.